Braeburn Receives Complete Response Letter for CAM2038 Injectable Buprenorphine Depot for the Treatment of Opioid Use Disorder

January 21, 2018

Responsive image

PRINCETON, N.J., Jan. 21, 2018 /PRNewswire/ — Braeburn Pharmaceuticals, Inc. (Braeburn) today announced that it has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the new drug application (NDA) for CAM2038, an investigational…

Category: Precious Metals